Search
Rocaglamide
go.drugbank.com/drugs/DB15495ExperimentalRocaglamide, also referred to as rocaglamide-A, is the eponymous member of a class of anti-cancer phytochemicals known as rocaglamides. … [A186760] Rocaglamide and a number of its derivatives (e.g.
Indomethacin
go.drugbank.com/drugs/DB00328ApprovedInvestigationalIndometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. … Intravenous indometacin is administered to close a hemodynamically significant patent ductus arteriosus, as indicated by clinical evidence, in premature infants.
Somatostatin
go.drugbank.com/drugs/DB09099ApprovedInvestigationalWithdrawn[DB00104] is a long-acting analogue of somatostatin that inhibits the release of a number of hormones, and is clinically used to relieve symptoms of uncommon gastroenteropancreatic endocrine tumours, as … Somatostatin is initially secreted as a 116 amino acid precursor, preprosomatostatin, which undergoes endoproteolytic cleavage to prosomastatin.
VA-MENGOC-BC®
go.drugbank.com/drugs/DB15800ExperimentalVA-MENGOC-BC is a meningococcal B and C vaccine and an outer membrane vesicle (OMV)-based vaccine. … Novel antigens such as γ-glutamyltranspeptidase, exopolyphosphatase, and a cell-binding factor protein were also identified with administration of this vaccine by a study.
ARCoV
go.drugbank.com/drugs/DB15855ExperimentalSARS-CoV-2 mRNA vaccine (ARCoV) is a novel mRNA coronavirus vaccine that consists of a lipid nanoparticle-encapsulated mRNA encoding the receptor binding domain of SARS-CoV-2[A220048]. … Manufactured as a liquid, ARCoV is thermostable at room temperature for at least 1 week.
Velpatasvir
go.drugbank.com/drugs/DB11613ApprovedInvestigationalVelpatasvir acts as a defective substrate for NS5A (Non-Structural Protein 5A), a non-enzymatic viral protein that plays a key role in Hepatitis C Virus replication, assembly, and modulation of host immune … a high barrier to resistance [L852].
Cannabidiol
go.drugbank.com/drugs/DB09061ApprovedInvestigationalFrom a pharmacological perspective, Cannabis' (and CBD's) diverse receptor profile explains its potential application for such a wide variety of medical conditions. … It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body.
UB-612
go.drugbank.com/drugs/DB16444InvestigationalThe vaccine incorporates a strong S1-RBD component linked to a single chain fragment region (sFC) of a human IgG1, which facilitates cell attachment and acts as the principal neutralizing domain of the … This vaccine was designed to induce a broad immune response. It was able to reduce viral load and prevent COVID-19 infection in a mouse challenge model and in rhesus macaques[L30653, L30658].
Efonidipine
go.drugbank.com/drugs/DB09235InvestigationalThe drug has been shown to block T-type in addition to L-type calcium channels [A7844, A32001]. It has also been studied in atherosclerosis and acute renal failure [A32001]. … Efonidipine is a calcium channel blocker of the _dihydropyridine class_, commercialized by Shionogi & Co. (Japan). Initially, it was marketed in 1995 under the trade name, _Landel_.